Apricus Biosciences Inc. (NASDAQ:APRI) Given Average Rating of “Hold” by Brokerages
Shares of Apricus Biosciences Inc. (NASDAQ:APRI) have earned an average rating of “Hold” from the five analysts that are currently covering the stock. Four analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $2.23.
Separately, Zacks Investment Research lowered Apricus Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, July 26th.
A hedge fund recently raised its stake in Apricus Biosciences stock. Healthcare Value Capital LLC boosted its stake in Apricus Biosciences Inc. (NASDAQ:APRI) by 83.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 440,000 shares of the company’s stock after buying an additional 200,000 shares during the period. Apricus Biosciences accounts for approximately 0.4% of Healthcare Value Capital LLC’s holdings, making the stock its 20th largest position. Healthcare Value Capital LLC owned about 0.71% of Apricus Biosciences worth $256,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 23.83% of the company’s stock.
Shares of Apricus Biosciences (NASDAQ:APRI) traded down 0.6669% during midday trading on Tuesday, hitting $0.3426. The stock had a trading volume of 272,717 shares. Apricus Biosciences has a 1-year low of $0.28 and a 1-year high of $1.68. The firm’s market cap is $22.73 million. The firm has a 50-day moving average price of $0.35 and a 200-day moving average price of $0.44.
Apricus Biosciences (NASDAQ:APRI) last released its earnings results on Thursday, August 4th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.03. During the same period in the previous year, the business posted ($0.10) earnings per share. On average, equities analysts anticipate that Apricus Biosciences will post ($0.17) EPS for the current fiscal year.
About Apricus Biosciences
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Ratings for Apricus Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.